Treatment and Diagnosis of Sexually Transmitted Diseases
- Sexually transmitted diseases are the most common infectious diseases in the U.S. More than 20 STDs have been identified, affecting more than 13 million men and women each year. The annual comprehensive cost of STDs in the U.S. is estimated to be well in excess of $10 to $18 billion.
- The total current U.S. market for new therapeutics and diagnostics for sexually transmitted diseases in 2000 reached $6.5 billion at the manufacturers' level. The growing numbers of sexually active teenagers and young adults of baby boomers has driven growth in this market. By 2005, it is anticipated that revenues will likely reach $9.4 billion, growing at an average annual growth rate of 7.8%. The total market for therapeutics and diagnostics for sexually transmitted diseases was dominated by the HIV/AIDS in 2000 with 37.1%.
- The products used in diagnosis and treatments of STDs are of extreme importance. Some STDs are declining in occurrence, while a number of fatal and highly uncomfortable diseases are proliferating. In the early to mid 1990s demographics helped cause decreasing incidence of some of these diseases. But the latter part of the century, when the children of baby boomers became sexually active has influenced the pendulum in the other direction.
The objective of the study is to present a comprehensive look at sexually transmitted diseases. Markets are divided according to diseases. Several of the products are used in multiple markets. The report is directed to decision-makers in the various areas of sexually transmitted disease markets to present insight into those arenas for current and future development.
REASONS FOR STUDY
This BCC study is presented to heighten the awareness of sexually transmitted diseases, their cause, and identify pharmaceutical preparations, devices and important advancements affecting markets within the sexually transmitted disease market. The study analyzes the new therapeutics and diagnostics for sexually transmitted diseases and it addresses issues and trends affecting the market. Manufacturers of pharmaceutical products, devices and test kits for sexually transmitted diseases have stepped up discovery, as the engine driving growth in all markets is research and development. Because of the evolving nature of the many areas of sexually transmitted diseases, executives involved in specific STD markets must remain ever vigilant of the changing environment and strive to keep abreast of current and potential opportunities.
SCOPE OF STUDY
The report is designed to be a comprehensive tool to provide an in-depth look at sexually transmitted diseases. The geographic scope of the report is the United States. The report identifies common sexually transmitted diseases; gives a brief explanation of the disease; cites risk factors, incidence and mortality; presents current treatments, and market size and participants. The report describes the industry in detail, its relationship to the healthcare industry, its participants, and its trends for the future.
New Therapeutics and Diagnostics for Sexually Transmitted Diseases is divided into categories by type of disease as follows:
- Bacterial Vaginosis
- Genital Herpes
- Genital Warts
- Hepatitis B
- Pediculosis Pubis
Each segment is discussed in detail, describing the disease, risk factors, incidence and mortality, identifying current products on the market in the base year 2000, measuring current and potential market size, identifying current and potential market drivers, forecasting for 2005, assessing current and potential competitors, and identifying current competitor market shares.
METHODOLOGY AND INFORMATION SOURCES
The information and analysis presented in this BCC report are based on extensive first hand interviews with primary executives, product managers, and clinical specialists in the areas of sexually transmitted diseases. Background information was obtained from various government, , medical journal and trade magazines and interviews with doctors and nurses. Key information from published literature was used to conduct interviews with over 92 industry participants to validate and obtain expert opinions on current and future trends in sexually transmitted diseases. Interviews were also used to confirm and/or adjust market size and market share estimates, as well as formulating market projections.
All market data pertain to the U.S. market at the manufacturer's level. Data are expressed in current U.S. dollars. The base year is 2000. Historical data are provided for 1998 and 1999 and forecast data are provided for 2005. Historical, base year and forecast data are provided for each market segment. Market shares are provided for each market segment for the 2000 base year.
Mary Anne Crandall is an RN/Instructor/Medical Analyst specializing in the pharmaceuticals industry.